Cancer Trial Results
ASCO 2020: Final Survival Results from SPARTAN, A Phase III Study of Apalutamide versus Placebo in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
Non metastatic castrate-resistant prostate cancer (M0 CRPC)
Mauricio Z. Baptista on Twitter: "SPARTAN Ph3 Rand Trial of Apalutamide vs Placebo in non mCRPC, Survival Results, New SOC is coming, #GU18 #pcsm #prostatecancer https://t.co/qG8gT3ke1W" / Twitter
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Page 46 - Monitoring Prostate Cancer to Guide Treatment Decision-Making
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis | Prostate Cancer and Prostatic Diseases
ASCO 2019: Age-Related Efficacy and Safety of Apalutamide plus Ongoing Androgen Deprivation Therapy in Subgroups of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of SPARTAN
Spartan - Speed meets obstacles. Race against the best in our Time Trial course Friday 6pm. | Facebook
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | NEJM
Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer
Spartan/Trial | Gumballs & Dungeons Wikia | Fandom
TAILOR-PCI is the largest trial of... - Spartan Bioscience | Facebook
Treating Non-Metastatic CRPC: The Evolving Landscape
Updates and Insights on the Medical Science of Prostate Cancer - ppt download
Mauricio Z. Baptista on Twitter: "SPARTAN Ph3 Rand Trial of Apalutamide vs Placebo in non mCRPC, Survival Results, New SOC is coming, #GU18 #pcsm #prostatecancer https://t.co/qG8gT3ke1W" / Twitter
NEJM al Twitter: "Among men with non-metastatic castration-resistant #prostatecancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. Full SPARTAN trial results: https://t.co ...
Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
Efficacy | ERLEADA® (apalutamide) HCP
